Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
StockWatch4
StockWatch4 Apr. 26 at 5:28 AM
$AZN pharmaceutical leader with strong oncology and global healthcare exposure
0 · Reply
lambyjams
lambyjams Apr. 25 at 7:54 PM
$ADTX Possible scenarios here... Bullish: New Ignite CEO Jeff Busch is a fixer. He's riling up $AZN by shopping around with competitors for exclusive use deals for their tech, uniquely suited to Antibody-Drug Conjugates, which AZ are intensely developing. AZ has already used and proved the tech, as per the last catalyst. Ignite sees an exclusive deal for their tech. Dilution will happen, but the proceeds will fund Aditxt, the parent company. With a big enough deal, dilution won't matter. Hero-scenario PT of $1-5. Bearish: The massive warrant offering at .50c is a bait. It'll act as an attractor, and once the stock hits .52 we'll see massive resistance. A few tens of millions of shares will get sold to suckers, they'll keep the lights on another few months while trying to solicit more funding or contracts. Company folds in 6m. Either way we'll probably see .50c Caveat: Even a massive buyout of Ignite by big pharma may screw investors.
1 · Reply
StockDudeIndy
StockDudeIndy Apr. 24 at 1:47 PM
$AZN So why is this down so much again today?
0 · Reply
Abouelyazeed
Abouelyazeed Apr. 24 at 11:58 AM
0 · Reply
JuanValdex
JuanValdex Apr. 23 at 3:08 PM
$BFRG $AZN has earnings next week. What did the brits pay for modella that they dont want to tell us.
0 · Reply
Abouelyazeed
Abouelyazeed Apr. 23 at 2:57 PM
$BFRG Every pharmaceutical company needs us to reduce clinical trial errors and accelerate the success of next-generation drugs 🚀🧬📈 $LLY $PFE $AZN $TEM
1 · Reply
Estimize
Estimize Apr. 21 at 12:03 PM
Wall St is expecting 2.52 EPS for $AZN Q1 [Reporting 04/29 BMO] http://www.estimize.com/intro/azn?chart=historical&metric_name=eps&utm_cont
0 · Reply
trenddetector
trenddetector Apr. 21 at 2:35 AM
$BMY $AZN $GSK $IBRX Gang, www.yourcancerpath.com has been updated with a plethora of useful tools for all types/subtypes of cancer. Please share it with friends and family. So much unbiased and useful info for cancer patients!
0 · Reply
Oknrv
Oknrv Apr. 20 at 11:02 PM
$CRDF soo... $AZN wanna "augment" their Enhertu's stamina?
0 · Reply
prismmarketview
prismmarketview Apr. 20 at 2:42 PM
$AZN #AstraZeneca Achieves Positive Phase III Results for COPD Drug https://prismmarketview.com/astrazeneca-achieves-positive-phase-iii-results-for-copd-drug/
0 · Reply
Latest News on AZN
Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Tue, 21 Apr 2026 08:50:59 -0400 - 4 days ago

Germany risks missing out on new drugs, AstraZeneca CEO tells paper


AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Mon, 20 Apr 2026 02:17:58 -0400 - 5 days ago

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups


AstraZeneca (AZN) Advances Portfolio with Strategic Update

2026-04-16T14:30:27.000Z - 9 days ago

AstraZeneca (AZN) Advances Portfolio with Strategic Update


AstraZeneca PLC: Result of AGM

2026-04-09T16:25:00.000Z - 16 days ago

AstraZeneca PLC: Result of AGM


Top Research Reports for AstraZeneca, HSBC & Walt Disney

2026-04-07T20:29:00.000Z - 18 days ago

Top Research Reports for AstraZeneca, HSBC & Walt Disney


Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Thu, 02 Apr 2026 17:34:00 -0400 - 23 days ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs


AstraZeneca stock jumps as COPD drug trial win surprises market

Fri, 27 Mar 2026 10:55:14 -0400 - 4 weeks ago

AstraZeneca stock jumps as COPD drug trial win surprises market


Stocks to Watch: Unity, Carnival, AstraZeneca

2026-03-27T14:00:29.000Z - 4 weeks ago

Stocks to Watch: Unity, Carnival, AstraZeneca


AstraZeneca Zips Higher On Its Double Win In COPD Treatment

2026-03-27T13:01:07.000Z - 4 weeks ago

AstraZeneca Zips Higher On Its Double Win In COPD Treatment


AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials

Fri, 27 Mar 2026 03:51:00 -0400 - 4 weeks ago

AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials


AstraZeneca drug reduces COPD flare ups in late-stage trials

Fri, 27 Mar 2026 03:18:47 -0400 - 4 weeks ago

AstraZeneca drug reduces COPD flare ups in late-stage trials


Final Trade: AZN, VIX, IWM

2026-03-26T22:06:21.000Z - 4 weeks ago

Final Trade: AZN, VIX, IWM


Top 3 Health Care Stocks That May Collapse This Quarter

Feb 18, 2026, 9:04 AM EST - 2 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

GERN MASI


AstraZeneca results: FY and Q4 2025

Feb 10, 2026, 7:00 AM EST - 2 months ago

AstraZeneca results: FY and Q4 2025


AstraZeneca Forecasts Continued Growth on Pipeline Strength

Feb 10, 2026, 2:34 AM EST - 2 months ago

AstraZeneca Forecasts Continued Growth on Pipeline Strength


AstraZeneca profit climbs on cancer and heart drug demand

Feb 10, 2026, 2:24 AM EST - 2 months ago

AstraZeneca profit climbs on cancer and heart drug demand


Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Feb 10, 2026, 2:06 AM EST - 2 months ago

Drugmaker AstraZeneca forecasts sales and profit growth in 2026


AstraZeneca begins trading on the New York Stock Exchange

Feb 2, 2026, 7:00 AM EST - 2 months ago

AstraZeneca begins trading on the New York Stock Exchange


AstraZeneca to delist from Nasdaq, join NYSE in February

Jan 20, 2026, 2:21 AM EST - 3 months ago

AstraZeneca to delist from Nasdaq, join NYSE in February


AstraZeneca to acquire Modella AI to speed oncology drug research

Jan 13, 2026, 12:10 PM EST - 3 months ago

AstraZeneca to acquire Modella AI to speed oncology drug research


StockWatch4
StockWatch4 Apr. 26 at 5:28 AM
$AZN pharmaceutical leader with strong oncology and global healthcare exposure
0 · Reply
lambyjams
lambyjams Apr. 25 at 7:54 PM
$ADTX Possible scenarios here... Bullish: New Ignite CEO Jeff Busch is a fixer. He's riling up $AZN by shopping around with competitors for exclusive use deals for their tech, uniquely suited to Antibody-Drug Conjugates, which AZ are intensely developing. AZ has already used and proved the tech, as per the last catalyst. Ignite sees an exclusive deal for their tech. Dilution will happen, but the proceeds will fund Aditxt, the parent company. With a big enough deal, dilution won't matter. Hero-scenario PT of $1-5. Bearish: The massive warrant offering at .50c is a bait. It'll act as an attractor, and once the stock hits .52 we'll see massive resistance. A few tens of millions of shares will get sold to suckers, they'll keep the lights on another few months while trying to solicit more funding or contracts. Company folds in 6m. Either way we'll probably see .50c Caveat: Even a massive buyout of Ignite by big pharma may screw investors.
1 · Reply
StockDudeIndy
StockDudeIndy Apr. 24 at 1:47 PM
$AZN So why is this down so much again today?
0 · Reply
Abouelyazeed
Abouelyazeed Apr. 24 at 11:58 AM
0 · Reply
JuanValdex
JuanValdex Apr. 23 at 3:08 PM
$BFRG $AZN has earnings next week. What did the brits pay for modella that they dont want to tell us.
0 · Reply
Abouelyazeed
Abouelyazeed Apr. 23 at 2:57 PM
$BFRG Every pharmaceutical company needs us to reduce clinical trial errors and accelerate the success of next-generation drugs 🚀🧬📈 $LLY $PFE $AZN $TEM
1 · Reply
Estimize
Estimize Apr. 21 at 12:03 PM
Wall St is expecting 2.52 EPS for $AZN Q1 [Reporting 04/29 BMO] http://www.estimize.com/intro/azn?chart=historical&metric_name=eps&utm_cont
0 · Reply
trenddetector
trenddetector Apr. 21 at 2:35 AM
$BMY $AZN $GSK $IBRX Gang, www.yourcancerpath.com has been updated with a plethora of useful tools for all types/subtypes of cancer. Please share it with friends and family. So much unbiased and useful info for cancer patients!
0 · Reply
Oknrv
Oknrv Apr. 20 at 11:02 PM
$CRDF soo... $AZN wanna "augment" their Enhertu's stamina?
0 · Reply
prismmarketview
prismmarketview Apr. 20 at 2:42 PM
$AZN #AstraZeneca Achieves Positive Phase III Results for COPD Drug https://prismmarketview.com/astrazeneca-achieves-positive-phase-iii-results-for-copd-drug/
0 · Reply
neo55
neo55 Apr. 18 at 7:01 PM
$IPHA $AZN have deal in place they can pay up to 850 million or like I always said they can buy $IPHA outright for 3-5 billion they already own 10% of company
0 · Reply
Kernmantel
Kernmantel Apr. 17 at 2:47 PM
$ABSI Why contract with Absci for new drug development? Just buy the company $MRK $AZN
0 · Reply
trenddetector
trenddetector Apr. 17 at 2:43 PM
$IBRX $LLY $GILD $AZN $BMY Too many updates to list. Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention. yourcancerpath.com/
0 · Reply
maikl_211
maikl_211 Apr. 17 at 1:19 PM
0 · Reply
Quantumup
Quantumup Apr. 15 at 8:31 PM
Leerink reiterated $GPCR Outperform; $90, and said: We view it as encouraging that Structure has hired a new executive with a track record of driving corporate value. MTSR - PFE $AZN $VKTX NVO LLY LYEL MYOV Here's what Leerink went on to say: https://x.com/Quantumup1/status/2044513105774891211?s=20
0 · Reply
BottomFisher_
BottomFisher_ Apr. 15 at 7:11 PM
$MLYS & Hypertension: Big Opportunities Ahead Here’s the real deal on the hypertension market: In the US, ~120M patients suffer from hypertension, with about half being treated and ~20M not reaching goal despite ≥2 therapies. A key culprit? Dysregulated aldosterone, which is estimated to contribute to ~30% of all cases. Enter $AZN and its baxdrostat—this one's set for approval in Q2, with $5B peak sales projected. There’s room for multiple winners in the ASI class, and given the size of the addressable market, we’re looking at huge growth potential. MGT also in the mix with lorundrostat but without much detail on their commercial strategy. However, it’s worth noting that ~60k US physicians are responsible for ~50% of prescriptions in the 3L+ setting, and ~60/40 split between PCPs and cardiologists. Big moves coming in hypertension. Eyes on $MLYS, $AZN, and $MGT.X for the next leg up.
1 · Reply
trenddetector
trenddetector Apr. 15 at 2:29 PM
$LLY $AZN $ROG I built the tool I wish I had 16 years ago. If you or a loved one is facing a diagnosis, don't navigate it in the dark. www.YourCancerPath.com is a free, anonymous way to map out diagnostic steps and find live clinical trials without the medical jargon. Pass it on—it could be a lifeline for someone today.
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 15 at 12:03 PM
$RADX The radiopharmaceutical sector is booming in 2026, driven by major investments in targeted cancer therapies (theranostics) and manufacturing expansion. Key updates include AstraZeneca's $15B investment, Telix Pharmaceuticals's… $AZN $TLX $NVS $SMMT
0 · Reply
shopno
shopno Apr. 15 at 12:25 AM
$ABBV $AZN $PFE $RVMD All these data based on Q4 2025. $MRK had 18B cash and 40B debts, so likely they were stringent on paying top premiums. In either case, I am absolutely fine if RVMD just does a partnership. Market valuation can go 50% over what anyone could pay (35-40B).
0 · Reply
shopno
shopno Apr. 15 at 12:20 AM
$RVMD $ABBV can’t afford 40B BO with <$6B cash on had and $63B debts! $AZN also got too little cash (6B), but their debts not as bad (25B). Like ABBV $PFE cannot afford RVMD— only 15B cash and massive 57B debts — $43B seagen acquisition in 2023 still not paying them off, as revenue just in $3B+ a year. PFE could afford acquiring SGEN, as they had 44B cash and 31B debt (net 13B cash) before the acquisition: https://www.macrotrends.net/stocks/charts/PFE/pfizer/long-term-debt BMS is bit better— 11B cash and 43B debts (net debt -32B). Roche is stronger financially with net debt -14B. LLY has large debts, but they have strong income growth. Not sure if they would ever acquire a company 5x of their highest ever acquisition!
0 · Reply
maikl_211
maikl_211 Apr. 14 at 5:20 PM
0 · Reply
Quantumup
Quantumup Apr. 13 at 8:25 PM
Stifel🏁 $TECX and said: We're initiating coverage of TECX with a Buy and $75 TP. $TENX $MRK IBIO $AZN Here's what else Stifel had to say: https://x.com/Quantumup1/status/2043785964942729374?s=20
0 · Reply